Corcept Therapeutics Seeks European Commission Approval for Cancer Therapy
What happened
Corcept Therapeutics announced that Europe’s drug regulator recommended approval for relacorilant, a cancer therapy already used in the US as Lifyorli. The recommendation was based on the pivotal Phase 3 ROSELLA trial, which showed patients on the combination therapy lived longer without disease progression than those receiving nab-paclitaxel alone. The European Commission is expected to issue its final decision in the fourth quarter of 2026.
From insidermonkey.com
Why it matters
The positive recommendation from the Committee for Medicinal Products for Human Use opens a market for the therapy in Europe. This market is expected to qualify for at least as many women for treatment as the US market.
Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
From insidermonkey.com
Who's involved
- Corcept TherapeuticsAmerican pharmaceutical company seeking European Commission approval for relacorilant
- Joseph K. BelanoffChief Executive Officer of Corcept Therapeutics
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Corcept TherapeuticsSpeculative
Corcept Therapeutics might gain market access in Europe, which could increase its revenue.
- Royal Bank of CanadaSpeculative
Royal Bank of Canada might see its investment holdings benefit from increased future revenue potential for Corcept Therapeutics.
Keep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company